Grupo de Estudos Multicentricos em Onco-Hematologia

5 in Phase 3

Quick facts

Phase 3 pipeline

Bortezomib, cyclophosphamide, thalidomide, dexamethasone · Oncology
This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing tumor necrosis factor, and providing immunomodulatory effects.
Thalidomide, Cyclophosphamide, Dexamethasone · Oncology
Thalidomide is a glutamic acid derivative that inhibits tumor necrosis factor-alpha (TNF-alpha) production, while Cyclophosphamide is an alkylating agent that interferes with DNA replication, and Dexamethasone is a corticosteroid that suppresses inflammation and immune response.
Thalidomide, Dexamethasone · Oncology
Thalidomide inhibits the release of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammation and immune response.
Thalidomide, Melphalan, Prednisone · Oncology
This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects.
Thalidomide plus dexamethasone · Oncology
Thalidomide acts as an immunomodulatory agent and cereblon E3 ligase ligand, while dexamethasone provides corticosteroid-mediated anti-inflammatory and immunosuppressive effects.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Grupo de Estudos Multicentricos em Onco-Hematologia

What is Grupo de Estudos Multicentricos em Onco-Hematologia's pipeline?

Grupo de Estudos Multicentricos em Onco-Hematologia has 5 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Bortezomib, cyclophosphamide, thalidomide, dexamethasone, Thalidomide, Cyclophosphamide, Dexamethasone, Thalidomide, Dexamethasone, Thalidomide, Melphalan, Prednisone.

Sector hub: All tracked pharma companies